Brief: UK's MHRA Approves Bayer's Sevabertinib To Treat Adults With HER2-Positive Lung Cancer
02/04/2026 10:19
April 2 (Reuters) - UK's MHRA: UK'S MHRA: SEVABERTINIB APPROVED TO TREAT ADULTS WITH HER2-POSITIVE LUNG CANCER THAT HAS SPREAD OR CANNOT BE REMOVED BY SURGERY Source text: [ID:] Further company coverage: [BAYGn.DE] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)